Azathioprine or 6-mercaptopurine for inflammatory bowel disease: do risks outweigh benefits?
- 30 September 2000
- journal article
- review article
- Published by Elsevier in Digestive and Liver Disease
- Vol. 32 (6) , 518-531
- https://doi.org/10.1016/s1590-8658(00)80010-9
Abstract
No abstract availableKeywords
This publication has 77 references indexed in Scilit:
- Inflammatory Bowel DiseaseNew England Journal of Medicine, 1996
- The clinical pharmacology of 6-mercaptopurineEuropean Journal of Clinical Pharmacology, 1992
- Inflammatory Bowel DiseaseNew England Journal of Medicine, 1991
- Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphismClinical Pharmacology & Therapeutics, 1989
- The effect of 6-mercaptopurine on natural killer-cell activities in Crohn's diseaseJournal of Clinical Immunology, 1985
- Shortcomings of the National Crohn's Disease Study: The exclusion of azathioprine without adequate trialGastroenterology, 1981
- Treatment of Crohn's Disease with Azathioprine: A Controlled EvaluationGastroenterology, 1974
- CONTROLLED TRIAL OF AZATHIOPRINE IN CROHN'S DISEASEThe Lancet, 1971
- CONTROLLED TRIAL OF AZATHIOPRINE IN CROHN'S DISEASEPublished by Elsevier ,1971
- AZATHIOPRINE FOR CROHN'S DISEASEThe Lancet, 1969